Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511Mark H. Norman, Paul E. Hughes, Bradley J. Herberich et al.|Journal of Medicinal Chemistry|2012Cited by 50
Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic StabilityMarkian M. Stec, Mark H. Norman, Kristin L. Andrews et al.|Journal of Medicinal Chemistry|2011Cited by 44
The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitorsMarkian M. Stec, Mark H. Norman, Kristin L. Andrews et al.|Bioorganic & Medicinal Chemistry Letters|2015Cited by 21
P450-Mediated O-Demethylated Metabolite Is Responsible for Rat Hepatobiliary Toxicity of Pyridyltriazine-Containing PI3K InhibitorsRaju Subramanian, Hervé Lebrec, Divesh Aidasani et al.|Toxicological Sciences|2014Cited by 7